The effects of FGF23 and Klotho on vascular calcification in end stage renal disease patients;

The effects of FGF23 and Klotho on vascular calcification in end stage renal disease patients; - FGF23 and vascular calcification

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47072

Enrollment

Registered

2018-04-20

Start date

2017-11-21

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease end stage renal failure.

Interventions

Vascular calcification

Pulse wave velocity

FGF23

Klotho

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Participating in the (pre)dialysis program Informed consent.

Exclusion criteria

Exclusion criteria: Age below 18 years. Withdrawal of consent.

Design outcomes

Primary

Measure	Time frame
Serum FGF23, Klotho and vitamin D concentrations and their correlation with arterial stiffness as measured by pulse wave velocity.	—

Secondary

Measure	Time frame
Correlation between carotid-femoral pulse wave velocity (cfPWV) and WeSTElan-derived PWV (wePWV).	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)